Speech overlooked as clinical marker, biotech says
Speech is an ‘underestimated’ clinical marker in neurodegenerative disease research, SynaptixBio has said.
The biotech, which became the only company to commercialise a treatment for the rare disease H-ABC, is set to launch a study into speech as a non-invasive, digital clinical marker in neurodegenerative disease research.
The study, in partnership with The Translational Centre for Speech Disorders at Murdoch Children’s Research Institute and facilitated by speech analytics company Redenlab, will assess speech as a clinical marker in H-ABC. The research will also consider communication styles including the use of sign language, gestures, devices, or other systems.
SynaptixBio has no active role in the study itself, but has facilitated contact with patients and patient advocacy groups in the UK and US. The research team is currently seeking to recruit patients aged six months to adulthood from all over the world.
“We are delighted to see this study get underway and keen to leverage Redenlab’s expertise in speech analysis for rare diseases to support our clinical research programme,” said Uwe Meya, Chief Medical Officer at SynaptixBio.
“The ability to communicate is often more important to patients and their families than other motor skills, and this is often underestimated by regulators.
“Despite the current lack of regulatory acceptance, we will use speech metrics as exploratory parameters in our intended clinical trials to inform our decision-making and support their validation for regulatory recognition.
“Speech parameters may be powerful tools for detecting early treatment effects prior to established clinical rating scales.”
